Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)
- 1Regeneron Pharmaceuticals, Inc, Tarrytown, NY
- 2SGS, Antwerp, Belgium
- 3Fortrea Clinical Research Unit, Leeds, United Kingdom
Abstract
Thrombosis is a major contributor to global morbidity and mortality. Current standards of care target the extrinsic and/or common pathways of coagulation, effectively inhibiting thrombosis but also increasing bleeding risk, highlighting the unmet need for additional treatment options. Genetic deficiency in factor XI (FXI), a component of the intrinsic pathway, reduces thrombosis risk without spontaneous bleeding. We generated 2 FXI monoclonal antibodies (mAbs) with distinct profiles to provide new approaches to anticoagulation. Cenvacibart (REGN7508Cat) targets the catalytic domain to completely block FXI activity (induced by activated FXII [FXIIa] or activated FXI [FXIa] in the intrinsic pathway or thrombin in the intrinsic/common pathway amplification loop), thereby maximizing anticoagulation. Amrecibart (REGN9933A2) targets the apple 2 domain of FXI/FXIa to specifically prevent FXI activity induced by FXIIa, delivering perhaps less anticoagulation but with potentially lower bleeding risk. We evaluated the anticoagulant effects of both mAbs in vitro in human and nonhuman primate plasma, in vivo in nonhuman primates, and healthy volunteers. Both mAbs inhibited intrinsic pathway–triggered coagulation, assessed by activated partial thromboplastin time (aPTT); cenvacibart exhibited a greater increase in aPTT vs amrecibart or other FXI-targeted inhibitors. Neither amrecibart nor cenvacibart affected the extrinsic pathway, assessed by prothrombin time (PT). In nonhuman primates, both mAbs prevented thrombosis without increasing bleeding. In first-in-human studies, both mAbs were generally well tolerated and dose-dependently inhibited intrinsic pathway–triggered coagulation, with durable aPTT prolongation without affecting PT. Amrecibart and cenvacibart may offer tailored therapies for patients with different bleeding risk profiles. These trials were registered at www.clinicaltrials.gov as NCT05102136 and NCT05603195.
Related
- Anticoagulation Monitoring in Recurrent Venous Thromboembolism Associated With Antiphospholipid Antibodies and Subsequent Heparin-Induced Thrombocytopenia.
- Efficacy and safety of FXI antibody cenvacibart compared with aspirin for venous thromboprophylaxis in patients after total knee arthroplasty (ROXI-ASPEN): study protocol for a phase 3, double-blinded, randomized trial
- Pulmonary inflammation in severe pneumonia is characterised by compartmentalised and mechanistically distinct sub-phenotypes
- Leveraging the Gut Microbiota for Mechanistically Informed Therapeutics against Body-First Parkinson's Disease.
- From dosage alteration to amplification strategies: mechanistically defined alpha-synuclein mouse models for Parkinson's disease therapy development.
BibTeX
@article{chalothorn2026anticoagulation,
title = {{Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)}},
author = {Dan Chalothorn and Aaron P. Kithcart and Ethan Marin and Selin Somersan-Karakaya and KehDih Lai and Frederic Cauwberghs and Jonathan Ackroyd and Kusha Mohammadi and Anju Shrestha and George Ehrlich and Ashique Rafique and Ishita Chatterjee and Kei Saotome and Matthew C. Franklin and Andrew J. Murphy and William Olson and Benjamin A. Olenchock and Gary A. Herman and David E. Gutstein and Andres Sirulnik and George D. Yancopoulos and Lori G. Morton},
journal = {Blood},
year = {2026},
month = jun,
doi = {10.1182/blood.2025032276},
url = {https://doi.org/10.1182/blood.2025032276},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)
AU - Dan Chalothorn
AU - Aaron P. Kithcart
AU - Ethan Marin
AU - Selin Somersan-Karakaya
AU - KehDih Lai
AU - Frederic Cauwberghs
AU - Jonathan Ackroyd
AU - Kusha Mohammadi
AU - Anju Shrestha
AU - George Ehrlich
AU - Ashique Rafique
AU - Ishita Chatterjee
AU - Kei Saotome
AU - Matthew C. Franklin
AU - Andrew J. Murphy
AU - William Olson
AU - Benjamin A. Olenchock
AU - Gary A. Herman
AU - David E. Gutstein
AU - Andres Sirulnik
AU - George D. Yancopoulos
AU - Lori G. Morton
PY - 2026
DA - 2026/06/15
JO - Blood
DO - 10.1182/blood.2025032276
UR - https://doi.org/10.1182/blood.2025032276
AB - Thrombosis is a major contributor to global morbidity and mortality. Current standards of care target the extrinsic and/or common pathways of coagulation, effectively inhibiting thrombosis but also increasing bleeding risk, highlighting the unmet need for additional treatment options. Genetic deficiency in factor XI (FXI), a component of the intrinsic pathway, reduces thrombosis risk without spontaneous bleeding. We generated 2 FXI monoclonal antibodies (mAbs) with distinct profiles to provide new approaches to anticoagulation. Cenvacibart (REGN7508Cat) targets the catalytic domain to completely block FXI activity (induced by activated FXII [FXIIa] or activated FXI [FXIa] in the intrinsic pathway or thrombin in the intrinsic/common pathway amplification loop), thereby maximizing anticoagulation. Amrecibart (REGN9933A2) targets the apple 2 domain of FXI/FXIa to specifically prevent FXI activity induced by FXIIa, delivering perhaps less anticoagulation but with potentially lower bleeding risk. We evaluated the anticoagulant effects of both mAbs in vitro in human and nonhuman primate plasma, in vivo in nonhuman primates, and healthy volunteers. Both mAbs inhibited intrinsic pathway–triggered coagulation, assessed by activated partial thromboplastin time (aPTT); cenvacibart exhibited a greater increase in aPTT vs amrecibart or other FXI-targeted inhibitors. Neither amrecibart nor cenvacibart affected the extrinsic pathway, assessed by prothrombin time (PT). In nonhuman primates, both mAbs prevented thrombosis without increasing bleeding. In first-in-human studies, both mAbs were generally well tolerated and dose-dependently inhibited intrinsic pathway–triggered coagulation, with durable aPTT prolongation without affecting PT. Amrecibart and cenvacibart may offer tailored therapies for patients with different bleeding risk profiles. These trials were registered at www.clinicaltrials.gov as NCT05102136 and NCT05603195.
SN - 0006-4971
SN - 1528-0020
ER -